Pay in 4 interest-free payments of $5.96 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
Withdraw the required volume using a sterile syringe and inject down the inside wall of the lyophilised vial
Contraindications Retatrutide is not appropriate for people with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN-2), or those with a history of pancreatitis
Its compounding status has been unsettled and repeatedly revised: the FDA placed ipamorelin (with CJC-1295) on the Category 2 "do not compound" bulks list in October 2023 citing insufficient safety data
This product is for laboratory research use only and must not be used in competitive athletics or for any human administration purposes
If a supplier believes that any information is inaccurate or that its rights are affected, it may contact Pharmaoffer to request review or removal
Patients with strong lifestyle habits sometimes maintain on 2.5 mg
US$ 23.35
US$ 24.34
US$ 27.79
US$ 25.63
US$ 22.49
US$ 23.07
